Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2021; 75(2): 111–117. doi: 10.48095/ccgh2021111.

Guidelines: for diagnosis and treatment of acute kidney damage in liver cirrhosis

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Angeli P, Ginès P, Wong F et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62(4): 986–994. doi: 10.1016/j.jhep.2014.12.029.
2. Huelin P, Piano S, Solà E et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic-liver failure. Clin Gastroenterol Hepatol 2017; 15(3): 438–445. doi: 10.1016/j.cgh.2016.09.156.
3. Davenport A, Sheikh MF, Lamb E et al. Acute kidney injury in acute-on chronic liver failure: where does hepatorenal syndrome fit? Kidney Int 2017; 92(5): 1058–1070. doi: 10.1016/j.kint.2017.04.048.
4. Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf) 2017; 5(2): 127– 137. doi: 10.1093/gastro/gox009.
5. Krones E, Fickert P, Zitta S et al. The chronic kidney disease epidemiology colloboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol 2015; 16: 196. doi: 10.1186/s128 82-015-0188-0.
6. Barreto R, Elia C, Solà E et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol 2014; 61(1): 35–42. doi: 10.1016/j.jhep.2014.02.023.
7. Belcher JM, Sanyal AJ, Peixoto AJ et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014; 60(2): 622–632. doi: 10.1002/hep.26980.
8. Solé C, Pole E, Solà E et al. Hepatorenal syndrome in the era of acute kidney injury. Liver Int 2018; 38(11): 1891–1901. doi: 10.1111/liv.13893.
9. Belcher JM, Garcia-Tsao G, Sanyal AJ et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57(2): 753–762. doi: 10.1002/hep.25735.
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69(2): 406–460. doi: 10.1016/j.jhep.2018.03.024.
11. Solà E, Kerbert AJ, Verspaget HW et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. J Hepatol 2016; 65(5): 914–920. doi: 10.1016/j.jhep.2016.07.003.
12. Kerbert AJ, Verbeke L, Chiang FW et al. Copeptin as an indicator of hemodynamic derangement and prognosis in liver cirrhosis. PloS One 2015; 10(9): e0138264. doi: 10.1371/journal.pone.0138264.
13. Adebayo D, Morabito V, Davenport A  et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 2015; 87(3): 509–515. doi: 10.1038/ki.2014.338.
14. Mandorfer M, Bota S, Schwabl P et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146(7): 1680–1690. doi: 10.1053/ j.gastro.2014.03.005.
15. Theocharidou E, Krag A, Bendtsen F et al. Cardiac dysfunction in cirrhosis – does adrenal function play a role? A hypothesis. Liver Int 2012; 32(9): 1327–1332. doi: 10.1111/j.1478-3231.2011.02751.x.
16. Weichselbaum L, Gustot T. The organs in acute-on-chronic liver failure. Semin Liver Dis 2016; 36(2): 174–180. doi: 10.1055/s-0036-1583 194.
17. Shah N, Mohamed FE, Jover-Cobos M et al. Increased renal expression and urinary excretion of TLR4  in acute kidney injury associated with cirrhosis. Liver Int 2013; 33(3): 398–409. doi: 10.1111/liv.12047.
18. Gustot T, Durand F, Lebrec D et al. Severe sepsis in cirrhosis. Hepatology 2009; 50(6): 2022–2033. doi: 10.1002/hep.23264.
19. Cavallin M, Piano S, Romano A et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a  randomized controlled study. Hepatology 2016; 63(3): 983–992. doi: 10.1002/hep.28396.
20. Nadim MK, Durand F, Kellum JA et al. Management of the critically ill patients with cirrhosis: a multidisciplinary perspective. J Hepatol 2016; 64(3): 717–735. doi: 10.1016/j.jhep.2015.10.019.
21. Afinogenova Y, Tapper EB. The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. Gastroenterol Rep (Oxf) 2015; 3(3): 216–221. doi: 10.1093/gastro/gov032.
22. Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a  dose-response meta-analysis. BMC Gastroenterol 2015; 15: 167. doi: 10.1186/s12 876-015-0389-9.
23. Singh V, Ghosh S, Singh B et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56(6): 1293–1298. doi: 10.1016/j.jhep.2012.01.012.
24. Cavallin M, Kamath PS, Merli M et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 2015; 62(2): 567–574. doi: 10.1002/hep.27709.
25. Song T, Rössle M, He F et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: a  systematic review and meta-analysis. Dig Liver Dis 2018; 50(4): 323–330. doi: 10.1016/j. dld.2018.01.123.
26. European Association for the Study of the Liver. EASL clinical practise guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53(3): 397–417. doi: 10.1016/j. jhep.2010.05.004.
27. ČHS ČLS JEP. Doporučený postup ČHS pro diagnostiku a léčbu hepatorenálního syndromu. [online]. Dostupné na: https://www.ces-hep. cz/file/323/doporuceny-postup-chs-hepatorenalni-syndrom.pdf.
28. Angeli P, Garcia-Tsao G, Nadim MK et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J  Hepatol 2019; 71(4): 811–822. doi: 10.1016/j. jhep.2019.07.002.

Kreditovaný autodidaktický test